Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialVsevolod Matveev, Se Hoon Park, Jae‐Lyun Lee et al.|The Lancet Oncology|2020Cited by 502
708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)Joaquim Bellmunt, Sophie Wildsmith, Thomas Powles et al.|Annals of Oncology|2021Cited by 2
13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristicsThomas Powles, Sophie Wildsmith, Michiel S. van der Heijden et al.|Annals of Oncology|2020Cited by 0